Print

A Study of the Drug REC-4881 For Treating People with Advanced Cancers with an APC or AXIN1 Mutation

https://www.facingourrisk.org/research-clinical-trials/study/290/a-study-of-the-drug-rec-4881-for-treating-people-with-advanced-cancers-with-an-apc-or-axin1-mutation

Clinicaltrials.gov identifier:
NCT06005974 (https://clinicaltrials.gov/show/NCT06005974)

Treatment
Treatment study for people with advanced cancer with an APC or AXIN1 mutation

Study Contact Information:

Study Contact: Recursion Pharmaceuticals
By phone: 385-374-1724
By email: clinicaltrials@recursionpharma.com

Tempus Labs
Study Contact: trials@tempus.com


About the Study

This study is looking at how well the research drug REC-4881 works and how safe it is for the treatment of people with advanced or metastatic cancers with an APC or AXIN1 mutation. REC-4881 is a type of targeted therapy drug known as a MEK1/2 inhibitor. 

What the Study Involves

Participants will be assigned to one of two groups based on the results of tumor testing. All participants will receive the drug REC-4881.

Participants will take REC-4881 once daily by mouth for up to 2 years. Follow up will include office visits, lab tests and imaging to track response to the treatment. 

Study Locations

Note: For all study locations, the contact is: trials@tempus.com.

Arizona

Arkansas 

California

Connecticut

Florida

Georgia

Illinois

Indiana

Louisiana

Maryland

Massachusetts

Missouri 

Nebraska 

Nevada

New Jersey

New York

North Dakota

Ohio

Oklahoma

Oregon

Pennsylvania

South Carolina

South Dakota

Texas

Utah

Virginia

Washington

Wisconsin


This Study is Open To:

This Study is Not Open To:

The following people are not eligible:


About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.